Indications
Rhapsido is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1 antihistamine treatment.
Composition
- Active substance
- remibrutinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Rhapsido
- Active substance
- remibrutinib
- ATC code
- L04AA60
- Therapeutic area
- Urticaria
- Marketing authorisation holder
- Novartis Europharm Limited
- Status
- Authorised
- EU authorisation
- 23 Apr 2026